220 related articles for article (PubMed ID: 8291115)
1. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection.
Cole EH; Cattran DC; Farewell VT; Aprile M; Bear RA; Pei YP; Fenton SS; Tober JA; Cardella CJ
Transplantation; 1994 Jan; 57(1):60-7. PubMed ID: 8291115
[TBL] [Abstract][Full Text] [Related]
2. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
[TBL] [Abstract][Full Text] [Related]
3. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
Hanto DW; Jendrisak MD; So SK; McCullough CS; Rush TM; Michalski SM; Phelan D; Mohanakumar T
Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
[TBL] [Abstract][Full Text] [Related]
4. The use of OKT3 in cadaveric renal transplantation for rejection that is unresponsive to conventional anti-rejection therapy.
Norman DJ; Barry JM; Bennett WM; Leone M; Henell K; Funnell B; Hubert B
Am J Kidney Dis; 1988 Feb; 11(2):90-3. PubMed ID: 3124611
[TBL] [Abstract][Full Text] [Related]
5. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
6. OKT3 for primary therapy of the first rejection episode in kidney transplants.
Tesi RJ; Elkhammas EA; Henry ML; Ferguson RM
Transplantation; 1993 May; 55(5):1023-9. PubMed ID: 8497875
[TBL] [Abstract][Full Text] [Related]
7. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
Malinow L; Walker J; Klassen D; Oldach D; Schweitzer E; Bartlett ST; Weir MR
Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
[TBL] [Abstract][Full Text] [Related]
8. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
Hariharan S; Alexander JW; Schroeder TJ; First MR
Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
[TBL] [Abstract][Full Text] [Related]
10. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis.
Barlow CW; Moon MR; Green GR; Gamberg P; Theodore J; Reitz BA; Robbins RC
Transpl Int; 2001 Aug; 14(4):234-9. PubMed ID: 11512056
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
13. Half dose of OKT3 is efficient in treatment of steroid-resistant renal allograft rejection.
Midtvedt K; Tafjord AB; Hartmann A; Eide TC; Holdaas H; Nordal KP; Draganov B; Sødal G; Leivestad T; Fauchald P
Transplantation; 1996 Jul; 62(1):38-42. PubMed ID: 8693541
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin after heart transplantation--increased morbidity with OKT3.
Macdonald PS; Mundy J; Keogh AM; Chang VP; Spratt PM
Transplantation; 1993 Jan; 55(1):110-6. PubMed ID: 8380508
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of OKT3 monoclonal antibody and anti-thymocyte globulin in the treatment of steroid-resistant acute allograft rejection in pediatric renal transplants.
Mochon M; Kaiser B; Palmer JA; Polinsky M; Flynn JT; Caputo GC; Baluarte HJ
Pediatr Nephrol; 1993 Jun; 7(3):259-62. PubMed ID: 8518094
[TBL] [Abstract][Full Text] [Related]
16. A pharmacoeconomic comparison of antithymocyte globulin and muromonab CD3 induction therapy in renal transplant recipients.
Brennan DC; Schnitzler MA; Baty JD; Ceriotti CS; Lowell JA; Shenoy S; Howard TK; Woodward RS
Pharmacoeconomics; 1997 Mar; 11(3):237-45. PubMed ID: 10165313
[TBL] [Abstract][Full Text] [Related]
17. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
18. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
[TBL] [Abstract][Full Text] [Related]
19. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation.
Rostaing L; Chabannier MH; Modesto A; Rouzaud A; Cisterne JM; Tkaczuk J; Durand D
Am J Nephrol; 1999; 19(6):634-40. PubMed ID: 10592356
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
